A Study to Compare Safety & Efficacy of Tramadol

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness and safety of tramadol hydrochloride (HCl) 37.5 miligram (mg)/acetaminophen 325 mg compared to gabapentin in participants with diabetic neuropathic (nerve disorder caused by diabetes mellitus) pain.

Clinical Trial Description

This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), multi-center and randomized (study drug is assigned by chance) study to compare the effectiveness and safety of tramadol HCl 37.5 mg/acetaminophen 325 mg with gabapentin in participants with diabetic neuropathy. The study will consist of 4 periods: Screening period (up to Day -14), Randomization period (Day 1), Dosage adjustment period (Day 15) and Maintenance period (Day 43). The participants will be randomly assigned to 1 of the 2 treatment groups: tramadol HCl 37.5 mg/acetaminophen 325 mg or gabapentin. Tramadol Hcl/acetaminophen group will receive 1 tablet for 3 days, then 1 tablet twice daily for 4 days followed by 1 tablet thrice daily for next 7 days. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Day 15 to 28, and then the increased dosage will be maintained for Day 29 to 42. Gabapentin group will receive 300 mg on Day 1, 300 mg twice daily on Day 2, and 300 mg thrice daily for Day 3 to 7. Then for Day 8 to 14, participants will receive 300 mg in the morning, 300 mg in the midday and 600 mg in the evening. If there is no pain relief, gabapentin can be increased up to 3600 mg per day for Day 15 to 28, and then the increased dosage will be maintained for Day 29 to 42. Primarily, efficacy will be evaluated by pain intensity using numeric rating scale (NRS). Participants' safety will be monitored throughout the study. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00634543
Study type	Interventional
Source	Janssen Korea, Ltd., Korea
Contact
Status	Completed
Phase	Phase 4
Start date	December 2006
Completion date	October 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04025320` - The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy	N/A
Completed	`NCT02659007` - Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga	Phase 1
Completed	`NCT01953757` - A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)	N/A
Completed	`NCT01707979` - NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes	N/A
Completed	`NCT00608439` - Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy	Phase 2
Completed	`NCT00576277` - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain	Phase 1/Phase 2
Completed	`NCT00830011` - Cognitive Behavioral Therapy for Painful Diabetic Neuropathy	N/A
Completed	`NCT00235443` - A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy	Phase 2/Phase 3
Completed	`NCT00931879` - Lovaza® and Microvascular Function in Type 2 Diabetes	Phase 4
Completed	`NCT00190970` - The Effect of Ruboxistaurin on Small Fiber Function	Phase 2
Completed	`NCT00101426` - Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy	Phase 3
Completed	`NCT00238550` - Study of CBME in the Relief of Painful Diabetic Neuropathy	Phase 2
Completed	`NCT05573685` - Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training	N/A
Recruiting	`NCT02341261` - Activity for Diabetic Polyneuropathy	N/A
Completed	`NCT01822925` - Study of DA-9801 to Treat Diabetic Neuropathy	Phase 2
Completed	`NCT01690962` - A Nutritional Intervention for Diabetic Neuropathy	N/A
Terminated	`NCT00993018` - A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy	Phase 2
Withdrawn	`NCT02315235` - The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy	N/A
Completed	`NCT00496457` - Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy	Phase 2
Recruiting	`NCT02606747` - The Balance Control Mechanism of DPN Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms